What is your preferred first-line treatment for metastatic gastric adenocarcinoma that is PD-L1 CPS ≥ 10 and also HER2+?

Very recently, trastuzumab has been replaced in the first-line setting by the results of the HERIZON-GEA-01 study, which evaluated zanidatamab, a bispecific/biparatopic antibody against 2 epitopes of HER2. This study randomized patients to the control arm of trastuzumab/chemotherapy (Arm A) versus z...

We all need to work together and bring the KN-811 regimen to the neoadjuvant setting for HER2+ve gastroesophageal adenocarcinoma patients. Giving FLOT-4 to HER2+ gastric or GEJ carcinoma patients doesn't make much sense in the post-KN-811 era... but we need data.